04:57 AM EDT, 06/24/2024 (MT Newswires) -- Novo Nordisk A/S ( NVO ) said on Sunday that a phase 3 study of its experimental therapy, Mim8, showed superior reductions in annualized bleeding rate compared to on-demand and prior prophylaxis treatment in patients with hemophilia A.

The company said patients with no prior prophylaxis treatment showed a reduction in the estimated mean annualized bleeding rate by 97.1% with once-weekly and 98.7% with once-monthly Mim8.

In the trial population with prior coagulation factor prophylaxis, Mim8 demonstrated a superior reduction in the estimated mean annualized bleeding rate by 48% for once-weekly and 42.6% for once-monthly treatment.

Novo Nordisk ( NVO ) said it plans to submit the data for the first regulatory approval by the end of 2024.

Price: 141.99, Change: +0.03, Percent Change: +0.02